Arrowhead Pharmaceuticals' investment case hinges on its RNAi platform and episodic milestone payments, which drove a $542.7M revenue spike in 2025Q2 but left non-milestone quarters with operating losses exceeding $140M. The company's escalating R&D spending (...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue is highly volatile, swinging from $2.5M to $542.7M in a single year, with 2025Q2 achieving a 70.2% operating margin, but non-milestone quarters show operating losses exceeding $140M, and R&D expenses have grown 104% since 2024Q2.
Arrowhead Pharmaceuticals uses cutting-edge scientific methods to develop and deliver novel therapies, potentially revolutionizing disease treatment.
The company maintains a robust investor relations platform, providing transparency and key business insights for stakeholders and analysts.
Detailed stock overviews, price targets, and earnings estimates are available, aiding informed investment decisions for ARWR.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$1.36-6.3% vs -$1.28 | $75M+70.4% vs $44M |
Q2 2026 May 7, 2026 | -$0.93+14.7% vs -$1.09 | $74M-0.1% vs $74M |
Q1 2026 Feb 5, 2026 | $0.22-63.3% vs $0.60 | $264M+23.4% vs $214M |
Q4 2025 Nov 25, 2025 | -$0.18-61.3% vs -$0.11 | $256M+46.3% vs $175M |
Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's
Benchmark ARWR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arrowhead Pharmaceuticals, Inc. (ARWR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $66.96 | $9.43B | -5488.52 | 23258.15% | -0.2% | -0.47% | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $12.33 | $1.38B | -3.24 | 16.92% | -672.16% | -57.79% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — |
Arrowhead Pharmaceuticals, Inc. (ARWR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 16, 2026·SEC
May 7, 2026·SEC
Get notified when ARWR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arrowhead Pharmaceuticals, Inc. (ARWR) stock FAQ — growth, dividends, profitability & financials explained
Arrowhead Pharmaceuticals, Inc. (ARWR) reported $669.5M in revenue for fiscal year 2025. This represents a 874028% increase from $0.1M in 1997.
Arrowhead Pharmaceuticals, Inc. (ARWR) grew revenue by 23258.2% over the past year. This is strong growth.
Arrowhead Pharmaceuticals, Inc. (ARWR) reported a net loss of $320.0M for fiscal year 2025.
Arrowhead Pharmaceuticals, Inc. (ARWR) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Arrowhead Pharmaceuticals, Inc. (ARWR) had negative free cash flow of $75.1M in fiscal year 2025, likely due to heavy capital investments.
